Project Grant K23HL175120
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $189K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- The University of Washington received a $880,735 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award will support research to examine the mechanisms through which cell lysis and leukotriene synthesis activate type-2 immunity in the lung. Key objectives include identifying alveolar macrophages as a source of leukotriene C4 and studying how its synthesis is regulated, as well as investigating...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $190,998 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant will fund a research project titled "Understanding Pulmonary Fibrosis Through the Integration of Complex Occupational and Environmental Exposure Assessments (PF-OEM)." The project aims to use epidemiological tools to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to a research partnership between Henry Ford Health and Michigan State University Health Sciences. The grant aims to identify drug compounds that can reverse profibrotic gene expression patterns in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with limited treatment options. Through a sub-award, Corewell Health will provide IPF...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
- This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $722,667 project grant to the University of Texas Health Science Center at Houston (UTHealth) to conduct research on ribosome dysfunction in lung fibrosis associated with systemic sclerosis (SSc). The 5-year project, spanning from September 1, 2025 to May 31, 2030, aims to investigate the mechanisms by which enhanced ribosome biogenesis leads to an altered...
- This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...